✦ LIBER ✦
9171 Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study
✍ Scribed by Tsai, C.; Griesinger, F.; Laskin, J.; Crinò, L.; Pavlakis, N.; Dansin, E.; Thatcher, N.; Ko, Y.D.; Metzger, J.; Garrido, P.
- Book ID
- 122777527
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 66 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.